Last update 12 Dec 2024
Falbikitug
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms AZD-0171 |
Target |
Mechanism LIF antagonists(Leukemia inhibitory factor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 263362643H
Source: *****
Sequence Code 263362647L
Source: *****
Related
4
Clinical Trials associated with FalbikitugA Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
100 Clinical Results associated with Falbikitug
Login to view more data
100 Translational Medicine associated with Falbikitug
Login to view more data
100 Patents (Medical) associated with Falbikitug
Login to view more data
100 Deals associated with Falbikitug
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | US | 10 Dec 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | CA | 10 Dec 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | KR | 10 Dec 2021 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 2 | ES | 10 Dec 2021 | |
| Non-Small Cell Lung Cancer | Phase 1 | US | 21 May 2018 | |
| Non-Small Cell Lung Cancer | Phase 1 | CA | 21 May 2018 | |
| Non-Small Cell Lung Cancer | Phase 1 | ES | 21 May 2018 | |
| Ovarian Cancer | Phase 1 | US | 21 May 2018 | |
| Ovarian Cancer | Phase 1 | CA | 21 May 2018 | |
| Ovarian Cancer | Phase 1 | ES | 21 May 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT03490669 (AACR2020) Manual  | Phase 1 | 41 | (14 in dose escalation; 27 in expanded cohorts) | mjamcwxjbo(vlhgwokbvs) = wukpkdqygj igbjzfdbhx (jhrkwreapq ) View more | Positive | 15 Aug 2020 | |
Phase 1 | 41 | yajolbdqio(hitsplkmzd) = 38 AEs (30 grade (Gr) 1,7 Gr 2, and 1 Gr 3), reported as possibly related to MSC-1 ionfvzqurq (eqcacqkcqg ) | - | 30 Sep 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free